Bayshore Pharmaceuticals LLC

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. The company s specialized sales force markets Abelcet, Oncaspar, Adagen and Depocyt in North America. In addition, it also receives royalties on sales of Peg-Intron, which is marketed by Schering-Plough Corporation, and Macugen, which is marketed by OSI Pharmaceuticals and Pfizer. The company s product-driven strategy includes a drug development program that leverages its proprietary technologies that includes a next-generation PEGylation platform that utilizes linkers designed to release compounds at a controlled rate. Internal research and development efforts are complemented with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. Enzon Pharmaceuticals is headquartered in Bridgewater, N.J.

Halo Pharmaceutical Inc, located in Whippany, NJ, specializes in formulation development and commercial manufacturing of complex therapeutics, offering a comprehensive range of dosage forms including solids, liquids, semi-solids, and specialty dosage types. As part of the Noramco Group, Halo Pharma leverages its state-of-the-art facilities and expertise to support pharmaceutical innovators and generics in taking their products from concept to commercialization. With a robust portfolio that includes nearly 120 active product development projects and a noteworthy record of regulatory approvals, Halo Pharma effectively meets the needs of its diverse clientele. The company's commitment to safety, quality, and collaboration positions it as a trusted partner for businesses seeking efficient drug product development and manufacturing solutions. Generated from the website

Prolong Pharmaceuticals, LLC, based in South Plainfield, NJ, is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for complex diseases, including ischemia, hypoxia within stroke, sickle cell disease, and cystic fibrosis. With a leadership team experienced in biotechnology and a pioneering approach to PEGylation, Prolong aims to meet critical unmet medical needs through its cutting-edge biopharma solutions. The company's flagship product, PP-007 Sanguinate, employs a novel PEGylated technology to restore homeostasis by delivering oxygen to hypoxic tissues and facilitating improved perfusion while reducing inflammation. Prolong Pharmaceuticals is committed to advancing healthcare through groundbreaking therapies targeting severe and life-threatening conditions, with a strong focus on addressing the global health issue of stroke. Generated from the website